Positive high-level results from the ADAURA phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival, a key secondary endpoint, compared to placebo in the adjuvant treatment of patients with early-stage (1B, 2 and 3a) epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe